CDK1 and lung carcinoma: Furthermore, Wee1 inhibition with adavosertib (MK1775) disrupts the G2/M checkpoint by preventing phosphorylation of cyclin-dependent kinase-1 (CDK1, cdc2), thereby inducing apoptosis in p53-mutant ovarian and lung cancer cells [16,17].